[Retracted] Efficacy, Safety, and Tumor Marker Inhibition of Apatinib Combined with Conventional Chemotherapy Regimens for Patients with Advanced Triple-Negative Breast Cancer

Table 3

The serum expression levels of Ki67, E-cadherin, and β-catenin between the conventional and combined groups before and after treatment.

Time	Group	Ki67	E-cadherin	β-Catenin
Before	Conventional (n = 75)	112.83 ± 10.65	74.01 ± 6.57	131.18 ± 14.72
	Combined (n = 75)	111.92 ± 10.76	74.21 ± 6.34	131.18 ± 14.22
t		0.175	0.271	0.162
		0.872	0.719	0.804
After	Conventional (n = 75)	82.26 ± 6.49^a	85.49 ± 6.47^a	120.01 ± 8.38^a
	Combined (n = 75)	57.82 ± 5.36^ab	102.81 ± 7.73^ab	101.15 ± 5.72^ab
t		8.213	7.982	9.092
		0.001	0.001	0.001

^a for comparison in the same group before and after treatment; ^b compared with the conventional group.